Difference between revisions of "WSI21-134"
From MGH Learn Pathology
(Edited automatically from page WSI21-134.) |
|||
(72 intermediate revisions by 12 users not shown) | |||
Line 1: | Line 1: | ||
− | {{ | + | {{ServiceRequest |
− | | | + | |intent=order |
− | | | + | |category=409073007 |
− | | | + | |priority=routine |
− | | | + | |code=study |
− | | | + | |orderDetail=order |
− | | | + | |authoredOn=July 06, 2021 01:07:32 PM |
− | | | + | |requester=Em99 |
− | | | + | |locationCode=learn |
− | | | + | |access=public |
+ | |subject=MGH | ||
+ | |performer=MGH | ||
+ | |supportingInfo=Cytology | ||
+ | |requisition=Cytology | ||
+ | |reasonCode=Pleural, Pericardial, and Peritoneal Fluids | ||
+ | }} | ||
+ | {{status | ||
+ | |status=completed | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Si787 | ||
+ | |authoredOn=March 10, 2022 10:38:21 AM | ||
+ | }} | ||
+ | {{status | ||
+ | |status=active | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Iac0 | ||
+ | |authoredOn=Jun 03, 2022 13:47:05 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=submitted | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Iac0 | ||
+ | |authoredOn=Jul 15, 2022 18:09:02 | ||
}} | }} | ||
{{status | {{status | ||
− | |requester= | + | |status=active |
− | |authoredOn= | + | |identifier=WSI21-134 |
− | + | |requester=Iac0 | |
+ | |authoredOn=Jul 15, 2022 18:09:10 | ||
}} | }} | ||
{{status | {{status | ||
+ | |status=submitted | ||
+ | |identifier=WSI21-134 | ||
|requester=Iac0 | |requester=Iac0 | ||
− | |authoredOn=Jul | + | |authoredOn=Jul 15, 2022 18:12:11 |
− | |status= | + | }} |
+ | {{status | ||
+ | |status=received | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Jul 19, 2022 14:19:17 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=active | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Jul 20, 2022 16:54:23 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=submitted | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Jul 20, 2022 17:32:46 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=received | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Jul 20, 2022 18:25:18 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=scanning | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Jul 22, 2022 14:36:18 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=completed | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Jul 22, 2022 14:36:48 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=active | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Ndk6 | ||
+ | |authoredOn=Sep 27, 2022 13:09:33 | ||
}} | }} | ||
{{status | {{status | ||
+ | |status=submitted | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Cfh13 | ||
+ | |authoredOn=Sep 27, 2022 17:05:55 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=received | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Rl391 | ||
+ | |authoredOn=Sep 28, 2022 11:22:35 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=scanning | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Sep 30, 2022 14:30:49 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=completed | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Oct 07, 2022 15:33:26 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=active | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Pab16 | ||
+ | |authoredOn=Oct 12, 2022 21:07:27 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=submitted | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Oct 17, 2022 20:27:34 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=received | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Oct 17, 2022 20:30:58 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=scanning | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Oct 19, 2022 12:57:05 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=completed | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Oct 24, 2022 17:35:59 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=active | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Ndk6 | ||
+ | |authoredOn=Nov 01, 2022 11:30:20 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=submitted | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Nov 15, 2022 14:16:58 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=received | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Nov 15, 2022 15:19:00 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=active | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Eh441 | ||
+ | |authoredOn=Nov 18, 2022 14:15:33 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=submitted | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Eh441 | ||
+ | |authoredOn=Nov 18, 2022 14:23:26 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=received | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Dec 05, 2022 15:53:51 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=scanning | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Dec 08, 2022 21:32:04 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=completed | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Dec 13, 2022 19:52:11 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=active | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Cfh13 | ||
+ | |authoredOn=Feb 06, 2023 18:55:16 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=submitted | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Cfh13 | ||
+ | |authoredOn=Feb 06, 2023 19:01:40 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=active | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Cfh13 | ||
+ | |authoredOn=Feb 06, 2023 19:14:54 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=submitted | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Cfh13 | ||
+ | |authoredOn=Feb 06, 2023 19:16:48 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=active | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Cfh13 | ||
+ | |authoredOn=Feb 06, 2023 19:17:14 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=submitted | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Cfh13 | ||
+ | |authoredOn=Feb 06, 2023 19:21:42 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=received | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Feb 08, 2023 14:17:31 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=scanning | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Feb 09, 2023 17:52:56 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=completed | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Feb 13, 2023 17:27:54 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=active | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Ez278 | ||
+ | |authoredOn=Feb 26, 2023 19:14:22 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=submitted | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Ez278 | ||
+ | |authoredOn=Feb 26, 2023 19:25:54 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=received | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Mar 03, 2023 14:06:20 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=scanning | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Mar 03, 2023 14:07:00 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=completed | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Mar 03, 2023 14:08:31 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=active | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Cfh13 | ||
+ | |authoredOn=Mar 23, 2023 16:47:54 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=submitted | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Cfh13 | ||
+ | |authoredOn=Mar 23, 2023 16:56:22 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=received | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Mar 28, 2023 12:59:08 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=scanning | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Mar 28, 2023 12:59:54 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=scanning | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Mar 28, 2023 13:00:59 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=completed | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=Apr 06, 2023 18:30:14 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=active | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Ndk6 | ||
+ | |authoredOn=Apr 13, 2023 20:04:39 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=submitted | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Aja51 | ||
+ | |authoredOn=May 15, 2023 12:43:08 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=active | ||
+ | |identifier=WSI21-134 | ||
|requester=Mlz8 | |requester=Mlz8 | ||
− | |authoredOn= | + | |authoredOn=May 19, 2023 19:05:08 |
− | |status= | + | }} |
+ | {{status | ||
+ | |status=submitted | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Mlz8 | ||
+ | |authoredOn=May 19, 2023 19:08:00 | ||
+ | }} | ||
+ | {{status | ||
+ | |status=active | ||
+ | |identifier=WSI21-134 | ||
+ | |requester=Iac0 | ||
+ | |authoredOn=May 25, 2023 20:12:03 | ||
}} | }} | ||
{{status | {{status | ||
+ | |status=submitted | ||
+ | |identifier=WSI21-134 | ||
|requester=Mlz8 | |requester=Mlz8 | ||
− | |authoredOn= | + | |authoredOn=Sep 01, 2023 11:51:57 |
− | |||
}} | }} |
Latest revision as of 06:52, September 1, 2023
Request details
Toggle columns: Diagnosis
Case | Clinical history | Requester |
---|---|---|
Case | Clinical history | Requester |
| 18-year-old male. History of glioblastoma. | Iac0 |
| 80yo M with left-sided pleural effusion | Mlz8 |
| 69yo F with pleural effusion | Mlz8 |
| 48M • kidney failure. Pleura FNA. | Iac0 |
| Over 90-year old male with significant asbestos exposure | Lcm51 |
| Pericardial effusion and history of parotid mass and atrial mass | Mlz8 |
| 33F. Peritoneal carcinomatosis. | Iac0 |
| 45 y/old F Long Hx of ESRD post kidney transplant. New effusion • duodenal mass and peritoneal nodules. | Lcm51 |
| 41M. History of clear cell sarcoma of finger. | Iac0 |
| 73y/old F with right pleural effusion and flank pain. | Aja51 |
| 60 y/old F with new pleural effusion and prior "soft tissue" tumor in the arm. | Aja51 |
| 79 yo male | Ndk6 |
| 50 yo female with history of metastatic carcinoma with bilateral pleural effusions | Ndk6 |
| 65 yo M with a history of myeloma. | Cfh13 |
| HISTORY OF MULTIPLE MYEOMA WITH PLASMACYTOMA. NOW HAS PLEURAL EFFUSIONS | Pab16 |
| 78 YO male with h/o adenocarcinoma of pyloric antrum and ascites | Ndk6 |
| Hx triple negative breast cancer | Est105 |
| 18-year-old man | Eh441 |
| 55 yo F with a remote history of breast carcinoma. | Cfh13 |
| 55 yo M with chronic pleural effusion. | Cfh13 |
| 52 yo F with acute respiratory failure in the setting of cocci and remote myeloma. | Cfh13 |
| 68yo man with a history of oncocytic thyroid carcinoma (metastatic to one lymph node) and clear cell renal cell carcinoma | Ez278 |
| 68 yo woman with an ovarian mass | Cfh13 |
| 73 yo man with ascites noted on surveillance following a Whipple for pancreatic carcinoma | Cfh13 |
| 27 yo F with unrescetable thymic carcinoma | Ndk6 |
| 80-year-old man | Njc35 |
| 49M • ascites fluid | Mlz8 |
| 69F. Pleural based mass. | Iac0 |
| 73 yo male | Dc679 |
| 34 yo male with left empyema and c/f lymphoma | Ndk6 |
| 75 yo male | Ndk6 |
| 72 yo female with thyroid cancer with recurrent right pleural effusion | Ndk6 |
| 67F. Pelvic mass. Pelvic ascites. | Iac0 |
| 62F. History of papillary thyroid carcinoma. Now with pleural effusion. | Iac0 |
| 20M. History of CNS lymphoma. | Iac0 |
| 87 YOF with with recurrent advanced pulmonary adenocarcinoma who recently developed myocarditis after Pembrolizumab and pleural effusion. | Tz046 |
Showing 1 to 36 of 36 entries